قَالَ رَسُولَ اللَّهِ ﷺ : مَا مَلَأَ آدَمِيٌّ وِعَاءً شَرًّا مِنْ بَطْنٍ بِحَسْبِ ابْنِ آدَمَ أُكُلَاتٌ يُقِمْنَ صُلْبَهُ فَإِنْ كَانَ لَا مَحَالَةَ فَثُلُثٌ لِطَعَامِهِ وَثُلُثٌ لِشَرَابِهِ وَثُلُثٌ لِنَفَسِهِ . رواه الترمذي وصححه الألباني
الثلاثاء، 23 فبراير 2021
Diet and your liver
Fibrosis and cirrhosis
Skip to 0 minutes and 14 secondsSo if we start with a healthy liver and injury it in some way, the liver will respond to that injury and try and repair it. This leads to scarring or fibrosis, which will resolve if the injury goes away. For example, if an infections is cleared. But if the injury persists, maybe in an inherited autoimmune condition, chronic fibrosis can persist until cirrhosis develops. And this can take up to 50 years in some people.
to 0 minutes and 43 secondsNow, whatever the cause of that causes injury, be it toxic damage to hepatocytes or an autoimmune attack on biliary cells, these damaged cells will release chemical signals.
to 0 minutes and 55 secondsThese signals will activate the stellate cells, which change their nature and start to divide and grow, and they produce the scar tissue.
to 1 minute and 5 secondsNow when the balance of scar tissue production and its normal breakdown is upset in this way, chronic disease develops ultimately leading to cirrhosis.
to 1 minute and 18 secondsWell, liver fibrosis is a process whereby the liver becomes damaged. Now that can either be very quickly or it can be over a long period of time. And the liver’s response to damage is to produce scar tissue. And it’s very like the scar tissue that you might see on someone’s skin after a bad cut or after a burn. It’s hard and it’s thick and it actually has no function. So, the liver starts to get replaced by thick scar tissue that doesn’t actually work like liver anymore. So in the beginning, scarring or fibrosis is something that the patient would have no symptoms from.
to 1 minute and 55 secondsAnd that’s one the problems with liver disease, is that you often have no symptoms in the early stages of disease. As that scar tissue builds up, that’s at the expense of useful cells like hepatocytes that function to do all the things that liver requires. And so, you actually find that you have lots of scar tissue and fewer functioning cells. And you start to find the liver begins to stop working. So fibrosis is scarring. That’s exactly what it means. But there are stages. And you might have a stage where there’s just a little bit of scar tissue, and that wouldn’t be a problem.
to 2 minutes and 29 secondsBut you can have a stage where there’s so much scar tissue that the liver actually begins to lose its function.
to 2 minutes and 39 secondsSo cirrhosis is the end stage of that. Now, cirrhosis is just a descriptive term. And so if you said to someone in the public, “What is cirrhosis?”, they say, well cirrhosis is what you get when you drink too much. But that’s not necessarily true because cirrhosis is what happens whichever liver injury you get. And it’s kind of the endpoint that all liver diseases reach. And it’s just a description of a stage of scarring, or fibrosis, that is so extensive that it changes the architecture, or the map, of how the liver looks underneath a microscope. And in its more advanced phases, cirrhosis is associated with this loss of function.
to 3 minutes and 19 secondsMainly because you lose all of the useful working liver cells because they’re replaced by scar tissue or isolated by the scar tissue into little islands.
to 3 minutes and 31 secondsThere are several stages to the fibrotic process. Doctor Holt mentioned architectural disruption of the liver in cirrhosis in the previous video. The image below builds on an example of the lobular organisation of liver tissue, which we used our Meet the Cells of the liver activity. We have shown the scar tissue in red in the illustration below.
to 3 minutes and 54 secondsThe first signs of mild fibrosis are evident when fibrous expansions are observed in the portal areas of the liver. Persistent damage can increase scar tissue deposits, which may join up between hexagonal liver lobules, forming bridges.
to 4 minutes and 10 secondsSevere disease is seen when lots of bridges start to cause destruction of liver lobules. During cirrhosis, the hexagonal lobular structures are disrupted by excessive scar tissue, that separates hepatocytes into isolated islands.
to 4 minutes and 27 secondsA pathologist would examine biopsy specimens and grade the quantity and location of fibrosis to come up with a score for a patient with liver disease. F0 represents no fibrosis, whilst F4 is cirrhosis.
to 4 minutes and 44 secondsCirrhosis has dramatic effects in the body. Development of advanced cirrhosis has consequences for many organs and systems other than the liver, itself. The built up of scar tissue makes it hard for blood to get into the liver and the pressure builds up. Similar to your home plumbing, increased resistance to flow leads to the development of back pressure, which alters the behaviour of veins in your abdomen. This can lead to the development of varices– which are like varicose veins– damage to other organs like your kidneys, and increased leakage of fluid into your abdomen which is causing ascites. All of these complications can be life-threatening.
to 5 minutes and 29 secondsResearchers are working hard to pursue multiple targets that may help patients with fibrotic livers. The primary target are hepatic stellate cells that produce fibrous deposits. Drugs can be potentially formulated to eliminate stellate cells, prevent their activation, or reverse it. Another valuable intervention would be to develop therapeutic agents that can break down scar tissue or stop it from forming.
to 5 minutes and 56 secondsAs secondary targets, scientists are looking to inhibit the accumulation of immune cells in the liver during inflammation, as these cells can activate stellate cells and cause scar tissue formation. The blue circles show examples of drugs and their mode of action. If you would like to know more, please have a look at the weblink’s further use of resources and the review we supplied in PDF.
الوقاية من الجلطات
أطعمة تقي من الجلطات
الزنجبيل: يعد حمض الساليسيليك من المكونات الأساسية للزنجبيل، وهو حمض طبيعي يساهم في منع حدوث الجلطات، كما يقلل من إحتمالية الإصابة بالسكتة الدماغية. وليس الزنجبيل وحده ما يحتوي على هذا الحمض، ولكن هناك أعشاب وتوابل أخرى غنية به، مثل الكركم، الزعتر، والنعنع، ومن الفواكه فتشمل الأناناس، التوت البري، العنب، والبرقوق.
الشوكولاتة الداكنة: حيث أنها غنية بالكاكاو الذي يحتوي على الفلافونيدات التي تمنع تخثر الدم وتكون الجلطة في الجسم، كونها تمنع تراكم الصفائح الدموية.
الثوم:
على الرغم من مذاقه غير المحبب للكثيرين، إلا أنه من أكثر المواد الغذائية التي تمنع الإصابة بالجلطات، لما له من تأثير في منع تراكم الصفائح الدموية التي تؤدي لحدوث الجلطة.
أنواع من الأسماك:
مثل سمك الماكريل، السردين، والسلمون، وكذلك زيت السمك، فكل هذه الأصناف تحتوي على الأوميغا 3 التي تعزز مستوى سيلان الدم وتعتبر مثبتات له وبالتالي تمنع تكون الجلطة، وتحمي من الإصابة بمختلف أمراض القلب.
ومن الأطعمة الأخرى الغنية بالأوميغا 3
زيت الكانولا، براعم الملفوف، السبانخ، وبذور الكتان.
البصل: يحتوي البصل على مادة الكيرستين المضادة للأكسدة، وتقوم هذه المادة بمنع إلتصاق صفائح الدم ببعضها.
الفطر الأسود: أيضاً يعمل الفطر الأسود على منع إلتصاق الصفائح الدموية ببعضها وكذلك تنظيف الدم، كما أنه غني بمادة الأدينوزين التي تقي الجسم من أمراض الشرايين والقلب.
فيتامين E: من الوسائل الفعالة لمنع تجلط الدم هو تناول الأطعمة التي تحتوي على فيتامين E، مثل المكسرات، صفار البيض، زيت جنين القمح، الحبوب الكاملة، البروكلي، والأفوكادو.
الطماطم: سواء كانت حبة الطماطم أو عصير الطماطم، فإن مركباتها تساعد في تثبيط تركم الصفائح الدموية التي تؤدي إلى التجلط في الدم. وهذه المركبات في الطماطم تشمل حمض الكلوروجينيك، حمض ب-كوماريك، وحمض الفيروليك. .
الأحد، 21 فبراير 2021
How the virus damage the liver
So the viruses themselves are probably in general, not directly, cytopathic. And by that, I mean that you can have large amounts of the virus in a cell, in the hepatocyte or liver cell, without that liver cell being damaged in any way. So it’s not the presence of the virus, which actually causes the damage, in general; it’s the body’s response to the damage, which is the key component in causation of liver injury. And what the immune system, what everybody’s immune system, is designed to do is to identify and to discriminate and to then eliminate foreign proteins.
0:55Skip to 0 minutes and 55 secondsSo that when a cell, a liver cell in this case, is infected with hepatitis virus, then some of the viral proteins should eventually make their way to the surface of that cell and be exposed to the exterior. So that the immune system can come along and have a sniff and decide whether there’s any foreign proteins in the cell. And if the immune system comes along and detects a viral protein, and recognises that as being a foreign protein, then a sequence of events should follow, where the immune system leads to the destruction of the infected hepatocyte. So it’s actually designed to eliminate the factories of the virus.
1:41Skip to 1 minute and 41 secondsThat’s a key component in elimination of the infection or otherwise other aspects of the immune response, which are important as well. But the key thing is that the hepatitis and the liver damage are due to the immune system’s recognition of an infected cell and then the elimination of that cell.
2:08Skip to 2 minutes and 8 secondsOK. So, without knowledge of the epidemiology of infection, and there are people who may have reason to believe that they’re at risk of being a carrier of Hepatitis So here I think we’re talking about, mainly about, well people who have put themselves at risk in some way, or have been at risk in some way, and therefore are keen to find out whether they might be a carrier. In some parts of the world, the prevalence of hepatitis carriage is so high that just being a member of that population is sufficient to encourage you to be tested.
2:53Skip to 2 minutes and 53 secondsFor instance, if we look at the first-generation Pakistani community in England, then we know that the prevalence of hepatitis carriage in that community is the same as the prevalence in their country of origin, in their region of origin. So that we’ve got a good idea, then, that there’s about a 1 in 20 chance that a British first-generation Pakistani would be a carrier of hepatitis, a 1 in 20 chance. So that’s a sufficient risk that that person should consider getting themselves tested. If you’ve ever injected drugs in the past, then you should seriously consider getting yourself tested for Hepatitis C infection.
3:39Skip to 3 minutes and 39 secondsAnd there are public health campaigns all over the world which are encouraging people who may have a history– often 30 years ago and often briefly– but if they’ve got any history of injecting drug use, then Hepatitis C infection is a distinct possibility. And the treatments are so good for chronic hepatitis now, but it’s important that people are diagnosed at a pre-symptomatic stage, even if they’ve got serious liver damage because death from liver disease can be prevented with good anti-viral therapy.
4:17Skip to 4 minutes and 17 secondsAcute hepatitis, in general, requires no anti-viral therapy. So the majority of people who get acute hepatitis will find they have a self-limiting and resolving illness. So anti-virals are not used in that setting. We usually just observe the patient to make sure that the liver damage does not get so severe. And anticipate recovery in the majority. So the treatment of viral hepatitis is really targeted towards people who are carriers of the infection. Remember, it’s carriers that have the chronic liver damage, and it’s the chronic liver damage that goes on to cirrhosis, liver failure, and liver cancer.
5:08Skip to 5 minutes and 8 secondsThe reason to treat the chronic hepatitis– and here we’re talking about Hepatitis B and Hepatitis C infection– is that if you can eliminate the virus or suppress the virus effectively and indefinitely, then you prevent further liver damage. Now for Hepatitis B, the paradigm is very much that of HIV treatment, in that our anti-virals that we use are very good at suppressing, but not very good at eliminating infection. So for the large majority of patients treated for Hepatitis B, we aim to suppress the virus to undetectable levels, and having done that, we’re confident that disease progression is prevented, and that recovery will start to occur.
6:01Skip to 6 minutes and 1 secondThe treatment paradigm for Hepatitis C is completely different from Hepatitis B and from HIV because it’s a short duration of therapy which aims to completely eliminate infection. And if you completely eliminate infection, then we see that same sequence of events– we prevent progression, we start to see a regression of liver damage, and we can be confident that the person we have treated will not suffer consequences of cirrhosis, like liver failure in the future.
6:32Skip to 6 minutes and 32 secondsHepatitis C treatment presently has been revolutionised because we’re going through a period where there’s been very active drug development and the drugs are incredibly effective against Hepatitis C. And some of them have been licenced quite recently in many countries around the world. The real challenge now is to make sure that the additional drugs come through, and that we can afford to treat patients with these anti-virals. That’s going to be one of the major challenges, I think, during the next 5 to 10 years– affordability rather than efficacy.
Autoimmune disease liver
so what is autoimmune liver disease, and what are the symptoms? Well they’re are a family of relatively rare liver diseases. Around– if we say 100 people with liver disease, around five of them will have an autoimmune liver disease. And by that we mean it’s a liver disease where their body attacks either their liver cells or their bile ducts. We like to think of them as a family of diseases, because they seem to be related, and often have symptoms and signs that are shared.
0:41Skip to 0 minutes and 41 secondsAnd the three diseases that we see as part of this family are autoimmune hepatitis– which we think of nestling in the middle of the family where the liver cells are inflamed and attacked by the immune system. And then there are two autoimmune bile duct diseases. The more common one is primary biliary cirrhosis, and that’s a disease that one in the 1,000 women over the age of 40 have. And that’s an immune attack on the small bile ducts, the so-called lymphocytic cholangitis. And then the rarer, large bile duct autoimmune disease is a disease that we give the name primary sclerosing cholangitis, and that’s a disease where there is fibrosis and sclerosis of the large bile ducts.
1:18Skip to 1 minute and 18 secondsAnd very commonly, those patients also have inflammation in their bowel, inflammatory bowel disease. Many patients actually have no symptoms of these diseases, but when they do have symptoms, they’re often fatigued, and sometimes they itch. And quite commonly, they are identified when they go to their doctors for either abdominal pain or routine testing, and their liver enzymes are high. And as a result, when we’ve excluded more common liver diseases, like alcohol and viruses, we start to think about the autoimmune liver disease family, and that’s when we try and make a diagnosis for them. Right, so who can get autoimmune liver disease? So, I mean these three diseases are actually seen in all ages, and in both men and women.
2:03Skip to 2 minutes and 3 secondsSo classically, primary biliary cirrhosis, that’s the small bile duct disease which is autoimmune, is seen in middle aged women in their 50s, and around 90% to 95% of patients are women. Primary sclerosing cholangitis is different. It can be seen in all ages, but the common age of presentation is between the age of 30 to 40. And it’s slightly more common in men. And as I said, the majority of patients, particularly if they’re white, will have inflammatory bowel disease. Autoimmune hepatitis can also be seen in all ages, so we have children with autoimmune hepatitis, and we have very elderly people with autoimmune hepatitis. But generally, people imagine that it’s a slightly more common disease in younger women.
2:46Skip to 2 minutes and 46 secondsAlthough, actually as we learn more about the disease and test more for it, we actually see it in all ages in both men and women. Probably about equal instance. Do we know what causes autoimmune liver disease? Well that’s the million dollar question. The answer is no. What we do know for sure is that autoimmune liver disease must occur for two reasons. One is that you’re predisposed to it genetically. And by that I mean in the loosest sense, you’ve got lots of different genes that predispose you to autoimmune attack on your liver. And then secondly, there must be something in the environment that triggers it.
3:19Skip to 3 minutes and 19 secondsSo when we look at the autoimmune liver diseases, we see that the patients and their families have all got other autoimmune diseases, and that sort of highlights why we think there’s a genetic association or risk for these diseases. And certainly the genetic studies that have been done in all three diseases really do confirm that there’s an association with the HLA system, which is a very important part of the immune system for presenting foreign things to the immune system, as well as other genes that are very important immune pathways. In terms of the environment, we’re quite clear that there must be environmental triggers.
3:53Skip to 3 minutes and 53 secondsAnd we know that, for example, we see patients with autoimmune hepatitis that follows some kind of drug injury– they take a medicine like nitrofurantonin, and they get a liver injury that looks like autoimmune hepatitis. We know that, for example, patients with PBC are more likely to be smokers, suggesting that there might be something in smoking which is an environmental trigger. As I told you, we know that patients with PSC have got inflammatory bowel disease, which makes us really wonder what’s going on in their bowel which may trigger their immune attack on their liver. So it’s a mixture of genes plus environment, and then they come together.
4:26Skip to 4 minutes and 26 secondsAnd then once the immune system’s out of the box, we find it hard to squidge it back in. So what should one do, if one thinks that they may have autoimmune liver disease? Well the first thing is it’s a diagnosis of exclusion. So it’s an important diagnosis to make, because it’s important for patients to be treated early. We all know that with any liver disease, it’s much better to treat the patient before they’ve got lots of scarring, before they’ve got cirrhosis. You’ve got a much better chance of reversing the damage before the damage is too significant. So patients should have their liver tests followed up.
5:02Skip to 5 minutes and 2 secondsAnd if there isn’t an obvious cause, such as being overweight, such as drinking too much, such as viral hepatitis B or C, then you need to seriously think about autoimmune liver disease, and they’ll go and see their gastroenterologist, or their hepatologist, who will go through a panel of tests, and particularly will look for patterns of blood tests, and patterns of immune markers that might help them. So, for example, when you’ve got a bile duct disease, your alkaline phosphatase is very high, so that’s a pattern that suggests bile duct inflammation. Whereas when you’ve got hepatitis, your AST or ALT your transaminases are very high.
5:35Skip to 5 minutes and 35 secondsSo your doctor will first of all say, well is it a hepatitis or a cholestasis, a biliary problem. And then they’ll either do some scans, ultrasounds or MRIs, and some immune tests. So, for example, we know that our patients have high globulins, and so if you have PBC your immunoglobulin M component is elevated. Whereas if you’ve got autoimmune hepatitis, it tends to be your immunoglobulin G. So that’s tests that they can do. And then, because these diseases are autoimmune diseases, some of them are associated with auto antibodies. So PBC, for example, 95% of our patients have got mitochondrial antibodies in their blood. In autoimmune hepatitis, we can pick up auto antibodies.
6:18Skip to 6 minutes and 18 secondsAnd so what their doctor does is put everything together, make sure what isn’t there, and then tries to work out whether it’s a bile duct problem, or a liver cell problem. Sometimes the patient still needs a liver biopsy. And liver biopsies are very important, because the pathologist can look under the microscope and can look at the pattern of inflammation and where it is, and try and work out what’s caused it. But more importantly tell you how severe it is. And once this is confirmed, what can one do to treat autoimmune hepatitis? Well, of all the autoimmune liver diseases, actually autoimmune hepatitis is the one that we can treat the best, although our patients don’t particularly always like the treatment.
6:56Skip to 6 minutes and 56 secondsSo for autoimmune hepatitis, that’s the most responsive to therapy, because if you give a patient steroids, you have a big impact on the immune system’s attack on the liver cells, and you can switch it off completely, actually. And you can then put the disease into remission, and you can use drugs like azathioprine or mycophenolate, which are more subtle immuno suppressants to keep the disease in remission. The autoimmune bile duct diseases are a little bit harder, actually. And they’ve been less responsive. Now, although they are autoimmune diseases, when you give drugs like steroids to patients, they don’t actually work, which is an interesting paradox.
7:30Skip to 7 minutes and 30 secondsBut for PBC, the more common bile duct disease, we give a drug called ursodeoxycholic acid, and that’s a very interesting drug, because actually that’s a bile acid that you make yourself. And we all have ursodeoxycholic acid in our bile, but it’s at a low level. And we supplement that pharmacologically, we make the urso levels quite high, and it’s a more nontoxic, less detergent, bile. And that seems very helpful for patients with PBC. It’s less helpful for patients with PSC. So currently, patients with PSC don’t have any therapies, and usually try and enter clinical trials. Patients with PBC only enter a clinical trial if they didn’t respond to ursodeoxycholic acid, which is about a third of patients.
8:09Skip to 8 minutes and 9 secondsAnd patients with autoimmune hepatitis would like new treatments, but they are trapped by the fact that it’s quite a rare disease, which is reasonably well treated with what we’ve got. But the patients don’t like the side effects, particularly of steroids.
حساب الكارب لمرضي السكر
تعد الكربوهيدرات من العناصر الغذائيّة الرئيسيّة الموجودة في الطعام والشراب، والتي تختلف بأنواعها؛ حيث توجد على شكل سُّكريات أو نشويات، أو أ...
-
قال الكاتب عبد العليم الحجار" سوائل أجسامنا" «أنهار تسري فينا» سوائل أجسامنا هي بمثابة «أنهار» فعلية تسري في سائر أرجاء الب...